ATLAS Space Operations Enhances Global Ground Station Network and Support for COSMIC-2 with Addition of a New Antenna in Rwanda
The Rwanda ground station receives data from six COSMIC-2 satellites, which continuously measure the Earth's atmosphere and ionosphere using radio occultation. The data collected by these spacecraft are crucial for accurate weather and space weather forecasting. Due to the dynamic nature of the atmosphere and ionosphere, rapid delivery of data to NOAA is paramount. ATLAS maintains a stringent requirement to deliver this data from its ground stations to NOAA in under 60 seconds.
This new site in Rwanda adds significant robustness to the ATLAS ground network, complementing existing ground stations in Ghana and Tahiti, also supporting the COSMIC-2 mission. Rwanda's unique geographic location offers an ideal number of contacts with the COSMIC-2 constellation, making it an exceptionally strategic asset for data reception. The addition of this site was requested by NOAA when it became available and ATLAS was able to offer this location through its strong partnership with the Rwanda Space Agency.
'The activation of our new antenna in Rwanda is a testament to the strength of our partnership with the Rwanda Space Agency and commitment to growing our network to best serve our customers,' said Corey Geer, Chief Executive Officer at ATLAS Space Operations. 'This strategic addition significantly enhances our ability to deliver critical COSMIC-2 data, ensuring that NOAA receives the vital information they need for accurate and timely atmospheric and ionospheric monitoring.'
ATLAS currently handles 3,000+ satellite contacts per month across its network. Since July 2019, as of May 31, 2025, ATLAS has successfully handled 156,653 contacts from NOAA satellites, maintaining a ground station availability of 99.36%. Furthermore, data has been delivered on average in under 40 seconds across all contacts, demonstrating ATLAS's commitment to efficiency and reliability.
About ATLAS Space Operations, Inc.
ATLAS Space Operations is the leading provider of Ground Software as a Service™ in the space communications industry. ATLAS' revolutionary Freedom® software has been recognized by industry-leading publications and organizations such as Via Satellite and CIO Review. Additionally, Aerospace & Defense Review named ATLAS the Space Tech Company of the Year (2024) and acknowledged ATLAS as one of the Top Satellite Solutions Providers (2024, 2023). Lastly, ATLAS was highlighted in the CIO Review: Telecom Edition as Company of the Year (2023), as well as one of the 10 Most Promising Technologies. ATLAS combines the Freedom Software Platform and its federated global antenna network to achieve its mission of securing space access anytime, anywhere. To learn more, visit atlasspace.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Astronomer Says the Object Approaching Us From Beyond the Solar System Is Not What We Think
Earlier this month, astronomers were thrilled to spot an interstellar object — only the third of its kind ever observed — hurtling toward the center of the solar system on an extremely unusual trajectory and at a breakneck velocity. While we're only beginning to understand the unusual object, dubbed 3I/ATLAS, the discovery led to widespread speculation, with some scientists suggesting that it may be almost as old as the Milky Way galaxy itself, and billions of years older than our own Sun. Unsurprisingly, Harvard astronomer Avi Loeb — who has extensively written about 'Oumuamua, the second interstellar object ever discovered, notably hypothesizing that it might have been a relic from an extraterrestrial civilization — has now waded into the discussion. In a blog post on Medium, he argued that it will take more observations to conclude the nature of 3I/ATLAS, which is likely either a comet or asteroid. However, Loeb didn't rule out the "tantalizing possibility" that it was "sent towards the inner solar system by design" — a conclusion that's already proved controversial. Loeb chided the editors of Wikipedia and the scientific journal RNAAS for striking the hypothesis from his contributions, showing once again that his theories about extraterrestrial probes visiting our solar system remain as contentious as ever. The astronomer has remained steadfast in his belief that 'Oumuamua, an interstellar object first observed in 2017, may have been sent to us by an alien civilization, garnering him enormous attention in the media. He has even gone on to hunt for pieces of what he claims may be an alien spacecraft, based on detections of a three-foot, interstellar meteor crash-landing near Papua New Guinea in early 2014, by combing the ocean floor with a modified ship. In other words, his latest comments about 3I/ATLAS are very much in line with what we'd expect from him. In his blog post, Loeb announced that he had authored a new paper about 3I/ATLAS' unusual size. Based on its "anomalously bright" nature, the astronomer concluded that the object was roughly 12.4 miles in diameter. That would make it considerably larger than 'Oumuamua, which only measured anywhere from 330 to 1,300 feet long. However, those calculations raise more questions than answers. The interstellar object's ' "size estimate makes little sense for an interstellar asteroid because the interstellar object 1I/'Oumuamua was 200 times smaller, and based on the statistics of asteroids in the Solar system, we should have discovered a million objects of the scale of 1I/'Oumuamua before spotting one interstellar object that is [roughly 12.4 miles] in diameter," Loeb wrote. "We know that [12.4-mile] asteroids are rare, because non-avian dinosaurs were killed by an asteroid half that size 66 million ago, whereas meter-scale asteroids impact the Earth every year," he added. However, subsequent observations forced Loeb back to the drawing board. Given the lack of "spectral fingerprints of atomic or molecular gas," 3I/ATLAS likely isn't a comet, as Loeb had initially suggested. "If 3I/ATLAS is not an asteroid — based on the interstellar reservoir argument in my paper, nor a comet — based on the lack of the spectral fingerprints of carbon-based molecules around it, then what is it?" Loeb asked rhetorically, highlighting his "by design" theory. Fortunately, there's still time for the scientific community to get a closer look. "The size anomaly of 3I/ATLAS will be easily clarified by upcoming data," Loeb wrote. As it "gets closer to the Sun, it will get brighter. If it is a solid object without a cometary plume of gas or dust around it, then its brightness will increase inversely with the square of the decreasing distance from the Sun times the square of the distance from Earth." "The simplest hypothesis is that 3I/ATLAS is a comet and we are missing the spectral features of its gaseous coma because of its large distance from Earth," he added. But without any observed cometary tail, Loeb suggests there's a chance we could be looking at evidence of an extraterrestrial visitor. "Let us instead maintain our childhood curiosity and seek evidence rather than pretend to be the adults in the room that know the answers in advance," he concluded."Science does not need to feel like a lecture in a classroom, summarizing past knowledge. It could be far more exciting if the teachers would be willing to learn something new!" More on 3I/ATLAS: The Interstellar Visitor Hurtling Toward the Center of Our Star System Is Unimaginably Ancient, Scientists Say Solve the daily Crossword
Business Wire
3 hours ago
- Business Wire
JCR Pharmaceuticals Selected for Japan's Regenerative Medicine CDMO Subsidy Program
HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR'), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has been selected for the Ministry of Economy, Trade and Industry's 'Regenerative CDMO Subsidy' as of July 15, 2025. The subsidy will support facility upgrades and equipment installation to expand biomanufacturing capacity for regenerative, cell, and gene therapies. Project Overview 1) Project Title JCR Regenerative Medicine CDMO Enhancement 2) Description Building on its expertise in regenerative medicine, JCR will strengthen its biomanufacturing capability through facility upgrades and workforce training. 3) Period Approval date – December 31, 2027 Background and Rationale Since the 2015 approval of TEMCELL ® HS Inj., JCR has steadily built expertise in regenerative medicine while ensuring a stable, long-term product supply. The company is now developing an AAV gene therapy platform, JUST-AAV, based on its proprietary J-Brain Cargo ® technology for delivery across the blood-brain barrier. To leverage these assets as a development and manufacturing partner for regenerative medicine products, JCR applied for this government subsidy to support manufacturing-related capital investment. Looking Ahead With this subsidy, JCR will invest not only in its own pipeline but also in new partnerships, strengthen as its role in biomanufacturing in regenerative and gene/cell therapies. About the Regenerative CDMO Subsidy Program This subsidy program supports the development of domestic CDMO (Contract Development and Manufacturing Organization) facilities and talent to ensure Japan's capacity to manufacture regenerative, cell, and gene therapies. For details, visit: (Japanese only). About JUST-AAV JUST-AAV is a proprietary platform technology that utilizes modified adeno-associated virus (AAV) vectors. The technology entails insertion of miniaturized antibodies against receptors on selected tissues, organs or the blood-brain barrier onto the capsid surface, enhancing targeted delivery to those tissues and organs. Further capsid modifications minimize off-target effects and improve safety. The name is derived from ' J CR' ' U ltimate destination of organ' ' S afeguarding against off-target delivery' and ' T ransformative technology' reflecting its potential for broad application across various diseases. About the J-Brain Cargo ® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO ® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as 'believe,' 'estimate,' 'anticipate,' 'intend,' 'plan,' 'will,' 'would,' 'target' and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions. This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.
Yahoo
6 hours ago
- Yahoo
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment Cross-study data show pelareorep increases PD-L1 expression and boosts cytotoxic T-cell activity, priming resistant tumors for checkpoint inhibitors Results reinforce pelareorep's ability to turn cold tumors hot, paving the way for registration-enabling trials SAN DIEGO and CALGARY, AB, July 16, 2025 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, summarized its biomarker and translational data for pelareorep, the Company's systemically delivered oncolytic virus. The data support pelareorep's mechanism of action and further strengthen the unique biological rationale and therapeutic potential for pelareorep as a platform immunotherapeutic. These include its ability to replicate in cancer cells, activate immune pathways, and drive T cell expansion and tumor infiltration in immunotherapy-resistant cancers. The translational research included the analysis of blood and tumor samples from patients in the GOBLET (pancreatic ductal adenocarcinoma (PDAC) and other gastrointestinal cancers) and AWARE-1 (breast cancer) studies. Analyses revealed consistent immune activation signatures, including: Upregulation of interferons, CXCL9/10/11, and PD-L1 Conversion of immunologically 'cold' tumors into 'hot' phenotypes Expansion and mobilization of tumor-infiltrating lymphocyte (TIL) clones in the blood, which correlates with a reduction in tumor size Modulation of the tumor microenvironment (TME) to enhance responsiveness to immune therapies "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME – all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." "The collection of data here show that pelareorep works how a cancer immunotherapy should work," said Jared Kelly, Chief Executive Officer of Oncolytics. "Pelareorep is a versatile product candidate with strong platform potential to enhance immunological responses in multiple indications, including hard-to-treat cancers. Such compelling findings should be exciting to strategic partners focused on finding a platform immunotherapy in large indications with high unmet medical needs." The GOBLET study continues to enroll PDAC and anal carcinoma patients, and additional translational data readouts are expected next year. The Company expects these and its other clinical data to support its focused and aggressive regulatory path and serve as the biological foundation for registration-enabled studies in immunotherapy-resistant solid tumors. As regulatory conversations progress throughout the summer, the Company expects to provide an updated clinical timeline before the end of the third quarter. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype – turning "cold" tumors "hot" – through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @oncolytics. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans, objectives and strategies; our expectation that our data supports our focused and aggressive regulatory path and serves as the biological foundation for registration-enabled studies in immunotherapy-resistant solid tumors; our plans to advance pelareorep into registration enabling studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon PattonDirector of IR & Communicationjpatton@ Investor Relations for OncolyticsMike MoyerLifeSci Advisors+1-617-308-4306mmoyer@ Media Contact for OncolyticsOwen BlaschakLifeSci Communicationsoblaschak@ Logo - View original content to download multimedia: SOURCE Oncolytics Biotech® Inc. View original content to download multimedia: Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
